The American Journal of Managed Care6h
Lipopolymer-Delivered RNA Interference Shows Promise Against FLT3-Mutated AML
Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients ...
Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference
PH-894: Potent and Specific Silencing of BRD4 in NK CellsMarlborough, Massachusetts--( - October 16, 2024) - Phio ...
Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst
Wave Life Sciences' WVE-006 study shows significant promise in treating alpha-1 antitrypsin deficiency. Learn more about WVE ...
AFP8h
Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Vutrisiran treatment leads to a decrease in serum vitamin A levels. Supplementation of approximately, but not exceeding, 2500 IU to 3000 IU vitamin A per day is advised for patients taking vutrisiran.